Black Rock Inc. 2seventy Bio, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,661,023 shares of TSVT stock, worth $11.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,661,023

Previous 3,905,405 6.26%

Holding current value

$11.4 Million

Previous $20.9 Million 32.54%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$3.6 - $5.79 $879,775 - $1.41 Million	-244,382 Reduced 6.26%	3,661,023 $14.1 Million
Q1 2024 May 10, 2024	SELL	$3.09 - $6.0 $19,525 - $37,914	-6,319 Reduced 0.16%	3,905,405 $20.9 Million
Q4 2023 Feb 13, 2024	SELL	$1.57 - $4.58 $791,413 - $2.31 Million	-504,085 Reduced 11.42%	3,911,724 $16.7 Million
Q3 2023 Nov 13, 2023	BUY	$3.14 - $11.2 $881,162 - $3.14 Million	280,625 Added 6.79%	4,415,809 $17.3 Million
Q2 2023 Aug 11, 2023	BUY	$8.45 - $12.48 $8.24 Million - $12.2 Million	974,661 Added 30.84%	4,135,184 $41.8 Million
Q1 2023 May 12, 2023	BUY	$9.21 - $14.98 $1.42 Million - $2.31 Million	153,911 Added 5.12%	3,160,523 $32.2 Million
Q4 2022 Feb 13, 2023	BUY	$8.57 - $17.0 $3.64 Million - $7.22 Million	424,476 Added 16.44%	3,006,612 $28.2 Million
Q3 2022 Nov 14, 2022	BUY	$12.56 - $17.54 $668,192 - $933,128	53,200 Added 2.1%	2,582,136 $37.6 Million
Q2 2022 Aug 12, 2022	BUY	$10.55 - $18.81 $9.87 Million - $17.6 Million	935,172 Added 58.68%	2,528,936 $33.4 Million
Q1 2022 May 12, 2022	SELL	$11.67 - $26.72 $104,084 - $238,315	-8,919 Reduced 0.56%	1,593,764 $27.2 Million
Q4 2021 Feb 10, 2022	BUY	$13.77 - $42.56 $22.1 Million - $68.2 Million	1,602,683 New	1,602,683 $41.1 Million

Others Institutions Holding TSVT

# of Institutions

126

Shares Held

45.6M

Call Options Held

122K

Put Options Held

19.8K

View Full List

About 2seventy bio, Inc.

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $118M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

More about TSVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account